This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.
Subjects must voluntarily participate in the study and sign an informed consent form;
Aged 18-75 years, male or female eligible；
ECOG performance status score of 0-1；
Expected survival ≥12 weeks；
History of other malignant tumors within the past 5 years；
Received systemic anti-tumor therapy within 4 weeks prior to the first study dose.
Surgical procedures requiring tracheal intubation and general anesthesia were performed within 4 weeks before the first administration, diagnostic or surface surgery was performed within 1 week before the first administration, or elective surgery was expected during the trial.
The study received radical radiotherapy within 4 weeks before the first medication ; and received palliative radiotherapy within 2 weeks before the first medication.